OPRD1 Recombinant Rabbit Monoclonal Antibody (SN20-04), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA532338-Each-of-1 | In Stock | ₹ 47,481.50 |
PIMA532338 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 47,481.50
GST (18%): ₹ 8,546.67
Total Price: ₹ 56,028.17
Antigen
OPRD1
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
TBS with 0.05% BSA, 40% Glycerol and 0.05% sodium azide, pH 7.4
Gene Accession No.
P32300, P33533, P41143
Gene Symbols
OPRD1
Immunogen
Synthetic peptide within Human OPRD1 aa 1-50
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Applications
Flow Cytometry, Western Blot
Clone
SN20-04
Conjugate
Unconjugated
Gene
OPRD1
Gene Alias
delta 1 opioid receptor, delta opioid receptor 1, delta-type opioid receptor, DOR, D-OR-1, DOR-1, K56, mDOR, MSL-2, Nbor, Opioid receptor, opioid receptor A, opioid receptor delta 1, opioid receptor, delta 1, OPRD, Oprd1, Ror-a
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
18386, 24613, 4985
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems
- The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits
- Then, individual clones are screened to select the best candidates for production
- The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire
- OPRD1 is an Opioid Receptor that is involved in the control of anxiety, depression, and pain
- It is a promising target in the therapy of mood-altering disorders and drug addiction
- Delta and kappa opioid receptors function synergistically by forming heterodimers
- OPRD1 expression has been reported primarily in the brain
- High OPRD1 expression has been documented in the cortex, caudate, hippocampus, nucleus accumbens, and putamen; low OPRD1 expression has been identified in the cerebellum, hypothalamus, substantia nigra, and thalamus
- OPRD1 expression is reduced in the putamen and amygdala of Alzheimer's patients and in the putamen in Parkinson's disease.